108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
金属有机框架介导的芦荟大黄素递送通过焦亡和免疫抑制协同作用增强肝细胞癌免疫治疗
Authors Xie H, Yi X, Huang K, Luo J, Zeng Q, He F, Wang L
Received 8 May 2025
Accepted for publication 28 August 2025
Published 23 September 2025 Volume 2025:20 Pages 11647—11667
DOI https://doi.org/10.2147/IJN.S533216
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Jie Huang
Huaying Xie,* Xiaoyuan Yi,* Kunzhao Huang, Jianzhang Luo, Qingyu Zeng, Feifei He, Liyan Wang
Digestive Department, Affiliated Hospital of Guilin Medical University, Guilin, 541001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Liyan Wang, Affiliated Hospital of Guilin Medical University, Lequn Road No. 15, Xiufeng District, Guilin, 541001, People’s Republic of China, Tel +86 15295953938, Email 168wangliyan@163.com
Purpose: Hepatocellular carcinoma (HCC) remains a major global oncological burden, with conventional therapies showing limited efficacy. This study aimed to utilize pyroptosis to alleviate the tumor’s immunosuppressive microenvironment, enhance systemic immunity, and improve immunotherapy efficacy, focusing on precise selection of pyroptosis inducers, immunotherapeutic agents, and drug delivery strategies.
Methods: After synthesizing AE-FeMn/FA, its morphology, particle size, and Zeta potential were characterized. We evaluated its catalytic performance in activating H2O2 to produce ·OH, ability to trigger cellular pyroptosis, and in vitro/in vivo anti-tumor effects. Combined with BMS-202, we explored suppression of the PD-1/PD-L1 complex and synergistic induction of pyroptosis.
Results: Intravenous AE-FeMn/FA targeted HCC, with controlled AE release triggering pyroptosis and anti-tumor immunity. BMS-202 alleviated immunosuppression, enhancing AE-FeMn/FA-induced anti-tumor responses, achieving synergistic immune-mediated cancer cell elimination.
Conclusion: The synergistic approach of pyroptosis combined with an enhanced immunotherapy nanoplatform shows promise as an effective HCC immunotherapy strategy, with significant clinical translation potential. Future studies will optimize the platform and conduct clinical trials.
Keywords: aloe-emodin, microenvironment response, pyroptosis, immunosuppressor, BMS-202
Digestive Department, Affiliated Hospital of Guilin Medical University, Guilin, 541001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Liyan Wang, Affiliated Hospital of Guilin Medical University, Lequn Road No. 15, Xiufeng District, Guilin, 541001, People’s Republic of China, Tel +86 15295953938, Email 168wangliyan@163.com
Purpose: Hepatocellular carcinoma (HCC) remains a major global oncological burden, with conventional therapies showing limited efficacy. This study aimed to utilize pyroptosis to alleviate the tumor’s immunosuppressive microenvironment, enhance systemic immunity, and improve immunotherapy efficacy, focusing on precise selection of pyroptosis inducers, immunotherapeutic agents, and drug delivery strategies.
Methods: After synthesizing AE-FeMn/FA, its morphology, particle size, and Zeta potential were characterized. We evaluated its catalytic performance in activating H2O2 to produce ·OH, ability to trigger cellular pyroptosis, and in vitro/in vivo anti-tumor effects. Combined with BMS-202, we explored suppression of the PD-1/PD-L1 complex and synergistic induction of pyroptosis.
Results: Intravenous AE-FeMn/FA targeted HCC, with controlled AE release triggering pyroptosis and anti-tumor immunity. BMS-202 alleviated immunosuppression, enhancing AE-FeMn/FA-induced anti-tumor responses, achieving synergistic immune-mediated cancer cell elimination.
Conclusion: The synergistic approach of pyroptosis combined with an enhanced immunotherapy nanoplatform shows promise as an effective HCC immunotherapy strategy, with significant clinical translation potential. Future studies will optimize the platform and conduct clinical trials.
Keywords: aloe-emodin, microenvironment response, pyroptosis, immunosuppressor, BMS-202